Logo
x

Search

Subscribe Now

Amneal

Amneal Expands its Partnership with mAbxience for Denosumab Biosimilars and Expanding Oncology Portfolio

Amneal Expands its Partnership with mAbxience for Denosumab Biosimilars and Expanding Oncology Portfolio

  • October 12, 2023
Amneal Reports P-III Study Results of IPX203 for the Treatment of Parkinson’s Disease

Amneal Reports P-III Study Results of IPX203 for the Treatment of Parkinson’s Disease

  • August 25, 2023
Amneal Receives Complete Response Letter on the NDA for IPX203 to Treat Parkinson’s Disease

Amneal Receives Complete Response Letter on the NDA for IPX203 to Treat Parkinson’s Disease

  • July 5, 2023
Amneal Receives NDA Approval from the US FDA for Pemrydi RTU

Amneal Receives NDA Approval from the US FDA for Pemrydi RTU

  • June 15, 2023
Amneal Reports the Commercial Availability of Fylnetra (biosimilar, pegfilgrastim) in the US

Amneal Reports the Commercial Availability of Fylnetra (biosimilar, pegfilgrastim) in the US

  • May 17, 2023
Amneal Launches Releuko (biosimilar, filgrastim) for the Treatment of Neutropenia

Amneal Launches Releuko (biosimilar, filgrastim) for the Treatment of Neutropenia

  • November 22, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.